Core sectors covered
Recession, a global pandemic, Brexit – it’s fair to say the events of the past decade have shaped the pharma industry landscape. How has it responded to these challenges and how can it make the most of future opportunities? How will innovation in product quality, manufacturing and working practise drive future productivity?
With the ever-increasing focus on personalised medicines, what strategies are we putting in place to ensure new drugs hit the 5Rs? Are we maximising clinical data? What does this mean for rare diseases?
How are tech giants and pharma companies collaborating to drive innovation in healthcare? What are the large pharma companies really looking for when it comes to new technologies, and at what stage will they pay for them? Is pharma manufacturing making the most of the digital revolution? Will COVID-19 change all of this?
- John Tsai - Head of Global Drug Development, Chief Medical Officer, Novartis
- Sir Menelas (Mene) Pangalos - Executive Vice President, BioPharmaceuticals R&D, AstraZeneca
- Andrew Plump - President, Research & Development, Takeda Pharmaceutical Company
Over 80 speakers broadcast live online makes Pharma Integrates a key event for over 450 delegates